Drug major Lupin on Wednesday announced that its subsidiary has entered into a licence and supply agreement with Galenicum Health for a diabetes and weight management drug.

Under the agreement, Lupin Atlantis Holdings SA (LAHSA) has partnered with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. Galenicum will be responsible for the development, manufacturing, and supply of the drug, while Lupin will manage regulatory filings, approvals, as well as commercialisation and distribution.

The product will be marketed across 23 countries, including Canada, Europe, Southeast Asia, and Latin America, the Mumbai-based pharmaceutical company said in a statement.